Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.53 |
| ▸ | SELP | P16109 | 7/20 | 0.51 |
| ▸ | SELL | P14151 | 5/20 | 0.51 |
| ▸ | VEGFA | P15692 | 4/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331511 | 0.90 | GAA (0.42) | TLR4SELPSELLVEGFAAKT1 | |
| SCHEMBL8331515 | 0.90 | GAA (0.42) | TLR4SELPSELLVEGFAAKT1 | |
| SCHEMBL258089 | 0.90 | SELP (0.57) | TLR4SELPSELLVEGFA | |
| SCHEMBL8150299 | 0.84 | IGF2R (0.53) | TLR4SELPVEGFA | |
| SCHEMBL8333751 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE | |
| SCHEMBL8334049 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE | |
| SCHEMBL15618321 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE | |
| SCHEMBL15618389 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE | |
| SCHEMBL1573005 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE | |
| SCHEMBL15618387 | 0.81 | SELL (0.59) | TLR4SELPSELLCETPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | KAO CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | TLR4 1588/4885SELP 1887/4885SELL 4413/4885 |
| US-20080234390-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | DSG1, CUTA, OGA | TLR4 1772/4885SELP 2149/4885SELL 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.